ARWR Arrowhead Pharmaceuticals PE ratio, current and historical analysis
The current PE ratio of ARWR cannot be calculated, as the latest EPS of -$5.16 is negative. Arrowhead Pharmaceuticals's last PE ratio on record was 287.7 in March 2020.
ARWR PE ratio history
The mean historical PE ratio of Arrowhead Pharmaceuticals over the last six years is 145.59. Looking back at the last six years, ARWR's PE ratio peaked in the Mar 2020 quarter at 287.7, with a price of $28.77 and an EPS of $0.1. The Sep 2019 quarter marked the lowest point at 39.14, with a price of $28.18 and an EPS of $0.72.
Arrowhead Pharmaceuticals PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $19.37 | -$5 |
| 2023 | N/A | N/A | $26.87 | -$1.92 |
| 2022 | N/A | N/A | $33.05 | -$1.67 |
| 2021 | N/A | N/A | $62.43 | -$1.36 |
| 2020 | N/A | N/A | $43.06 | -$0.84 |
| 2019 | 39.14 | N/A | $28.18 | $0.72 |
| 2018 | N/A | N/A | $19.17 | -$0.65 |
| 2017 | N/A | N/A | $4.33 | -$0.47 |
| 2016 | N/A | N/A | $7.35 | -$1.34 |
| 2015 | N/A | N/A | $5.74 | -$1.6 |
| 2014 | N/A | N/A | $14.77 | -$1.25 |
| 2013 | N/A | N/A | $5.69 | -$1.3 |
| 2012 | N/A | N/A | $2.62 | -$1.9 |
| 2011 | N/A | N/A | $3.9 | -$0.44 |
| 2010 | N/A | N/A | $10.5 | -$0.9 |
Arrowhead Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | N/A | N/A | $18.8 | -$5.16 |
| Sep 2024 | N/A | N/A | $19.37 | -$5 |
| Jun 2024 | N/A | N/A | $25.99 | -$4.66 |
| Mar 2024 | N/A | N/A | $28.6 | -$4.24 |
| Dec 2023 | N/A | N/A | $30.6 | -$2.76 |
| Sep 2023 | N/A | N/A | $26.87 | -$1.92 |
| Jun 2023 | N/A | N/A | $35.66 | -$1.7 |
| Mar 2023 | N/A | N/A | $25.4 | -$1.42 |
| Dec 2022 | N/A | N/A | $40.56 | -$1.46 |
| Sep 2022 | N/A | N/A | $33.05 | -$1.67 |
| Jun 2022 | N/A | N/A | $35.21 | -$1.47 |
| Mar 2022 | N/A | N/A | $45.99 | -$1.08 |
| Dec 2021 | N/A | N/A | $66.3 | -$1.76 |
| Sep 2021 | N/A | N/A | $62.43 | -$1.36 |
| Jun 2021 | N/A | N/A | $82.82 | -$1.23 |
ARWR average PE ratio chart
ARWR PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| JNJ Johnson & Johnson | 26.6 | $374.05B |
| ALNY Alnylam Pharmaceuticals Inc | N/A | $34.54B |
| INO Inovio Pharmaceuticals Inc | N/A | $60.87M |
| LGND Ligand Pharmaceuticals Inc | N/A | $2.09B |
| MRNA Moderna Inc | N/A | $10.69B |
| ARWR Arrowhead Pharmaceuticals Inc | N/A | $1.6B |
Frequently asked questions
What is Arrowhead Pharmaceuticals's PE ratio?
The current price to earnings ratio of ARWR cannot be determined, as its EPS of -$5.16 is negative.
What is the highest PE ratio for ARWR?
The highest quarterly PE ratio in the last six years has been 287.7 and it was in the Mar 2020 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.